Alterity Therapeutics Limited
ATH
株式のランク
#26019
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997,... Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
株価
$0.1904269
時価総額
$41.61M
変化（1日）
-3.57%
変化（1年）
-45.59%
国
AU
取引 Alterity Therapeutics Limited (ATH)
カテゴリー
Healthcare
Alterity Therapeutics Limited（ATH）のP/S比率
2026 時点のP/S比率 TTM: 0
Alterity Therapeutics Limited の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Alterity Therapeutics Limited の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
